Overview
Amy Calati is an Oncologist and a Hematologist in Detroit, Michigan. Dr. Calati is rated as an Experienced provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, and Non-Muscle Invasive Bladder Cancer. Dr. Calati is currently accepting new patients.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- HMO
- POS
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
2799 W Grand Blvd, Detroit, MI 48202
Regents Of The University Of Michigan
John Krauss is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Krauss is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Anal Cancer. Dr. Krauss is currently accepting new patients.
University Physician Group
Anthony Shields is a Hematologist Oncology specialist and a Hematologist in Detroit, Michigan. Dr. Shields is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Anal Cancer, and Pseudomyxoma Peritonei. Dr. Shields is currently accepting new patients.
Oakland Medical Group - Division Of Clinical Hematology & Medical Oncology - Royal Oak
Maryann Shango is a Hematologist and an Oncologist in Royal Oak, Michigan. Dr. Shango has been practicing medicine for over 15 years and is rated as an Advanced provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are HER-2 Positive Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Pseudomyxoma Peritonei. Dr. Shango is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Breast CancerDr. Calati isAdvanced. Learn about Breast Cancer.
- Muscle Invasive Bladder CancerDr. Calati isAdvanced. Learn about Muscle Invasive Bladder Cancer.
- Non-Muscle Invasive Bladder Cancer
- Paget Disease of the BreastDr. Calati isAdvanced. Learn about Paget Disease of the Breast.
- Pleuropulmonary BlastomaDr. Calati isAdvanced. Learn about Pleuropulmonary Blastoma.
- Polycythemia VeraDr. Calati isAdvanced. Learn about Polycythemia Vera.
- Experienced
- Acinic Cell Carcinoma of Salivary Glands
- Adult Immune ThrombocytopeniaDr. Calati isExperienced. Learn about Adult Immune Thrombocytopenia.
- Adult Soft Tissue SarcomaDr. Calati isExperienced. Learn about Adult Soft Tissue Sarcoma.
- AgranulocytosisDr. Calati isExperienced. Learn about Agranulocytosis.
- Anal CancerDr. Calati isExperienced. Learn about Anal Cancer.
- Anaplastic Large Cell LymphomaDr. Calati isExperienced. Learn about Anaplastic Large Cell Lymphoma.